A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
暂无分享,去创建一个
G. Knudsen | H. D. Hansen | B. Ozenne | N. Raval | A. Johansen | L. Donovan | N. F. Ros | Annette Johansen | Nídia Fernandez Ros
[1] G. Knudsen,et al. Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig , 2020, European Neuropsychopharmacology.
[2] M. Liechti,et al. Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers , 2020, ACS pharmacology & translational science.
[3] Matthew W. Johnson,et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder , 2020, JAMA psychiatry.
[4] J. Riba,et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo , 2020, Translational Psychiatry.
[5] F. Vollenweider,et al. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders , 2020, Nature Reviews Neuroscience.
[6] C. Halldin,et al. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain. , 2020, Synapse.
[7] Sara Marmolejo-Martínez-Artesero,et al. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins , 2019, European Neuropsychopharmacology.
[8] D. Val-Laillet,et al. Validation of a Psychosocial Chronic Stress Model in the Pig Using a Multidisciplinary Approach at the Gut-Brain and Behavior Levels , 2019, Front. Behav. Neurosci..
[9] K. Blennow,et al. Synaptic vesicle protein 2A as a potential biomarker in synaptopathies , 2019, Molecular and Cellular Neuroscience.
[10] Dustin Scheinost,et al. Lower synaptic density is associated with depression severity and network alterations , 2019, Nature Communications.
[11] C. Svarer,et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels , 2019, Neuropsychopharmacology.
[12] Kwang H. Choi,et al. Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in the prefrontal cortex, amygdala, and hippocampus of Sprague-Dawley rats , 2019, IBRO reports.
[13] A. van Waarde,et al. Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging , 2018, Medicinal research reviews.
[14] D. E. Olson,et al. Psychedelics Promote Structural and Functional Neural Plasticity , 2018, Cell reports.
[15] A. Feilding,et al. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro , 2017, Scientific Reports.
[16] R. Franzen,et al. Puzzling Out Synaptic Vesicle 2 Family Members Functions , 2017, Front. Mol. Neurosci..
[17] Matthew W. Johnson,et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.
[18] B. Schmidt,et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.
[19] M. Liechti,et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.
[20] D. Spencer,et al. Imaging synaptic density in the living human brain , 2016, Science Translational Medicine.
[21] James Rucker,et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.
[22] Claus Svarer,et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin , 2016, NeuroImage.
[23] Claus Svarer,et al. A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System , 2017, The Journal of Neuroscience.
[24] Gitte Moos Knudsen,et al. Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain , 2014, NeuroImage.
[25] J. González-Maeso,et al. P.1.g.022 Hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists induce distinct patterns of G protein coupling in postmortem human brain , 2013, European Neuropsychopharmacology.
[26] J. Palacios,et al. Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI , 2013, Experimental Brain Research.
[27] M. Banasr,et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. , 2013, The international journal of neuropsychopharmacology.
[28] Claus Svarer,et al. Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36 , 2013, Molecular Imaging and Biology.
[29] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[30] G. Rajkowska,et al. Decreased Expression of Synapse-Related Genes and Loss of Synapses in Major Depressive Disorder , 2012, Nature Medicine.
[31] Amy L. Nowack,et al. SV2 regulates neurotransmitter release via multiple mechanisms. , 2010, American journal of physiology. Cell physiology.
[32] Michael Kometer,et al. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.
[33] G. Réus,et al. Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus , 2010, Journal of neural transmission.
[34] Ryan T. Strachan,et al. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling , 2009, Proceedings of the National Academy of Sciences.
[35] D. Hanniford,et al. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes. , 2005, Assay and drug development technologies.
[36] Bryan L Roth,et al. Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists , 2001, Brain Research Bulletin.
[37] M. Loza,et al. Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. , 2001, Molecular pharmacology.
[38] V. Watts,et al. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. , 2000, Journal of medicinal chemistry.
[39] J. Hensler,et al. Regulation of 5-HT2A receptor mRNA levels and binding sites in rat frontal cortex by the agonist DOI and the antagonist mianserin , 2000, Neuropharmacology.
[40] Donatella Marazziti,et al. Distribution and characterization of [3H]mesulergine binding in human brain postmortem , 1999, European Neuropsychopharmacology.
[41] B. Roth,et al. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. , 1996, Molecular pharmacology.
[42] M. Pompeiano,et al. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. , 1994, Brain research. Molecular brain research.
[43] D. X. Freedman,et al. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. , 1988, Life sciences.
[44] R. Lefkowitz,et al. A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. , 1980, Molecular pharmacology.
[45] R. Mowbray,et al. HALLUCINOGENS , 1970, The Medical journal of Australia.